11/10/2026
The 2026 ANZ Sarcoma Association Annual Scientific Meeting, Sarcoma 2026: From Innovation to Recovery, brought the promise of emerging science closer to the people at the heart of our work.-those living with sarcoma & their families
CRBF works to identify credible, evidence-based opportunities, support families through complex decisions, connect people with specialist expertise, & strengthen collaboration across research, clinical care & support services.
The comprehensive programme over two days included presentations from international sarcoma research/clinicians Dr Ashleigh Guadagnolo from MD Anderson & Professor Craig Gerrand from the Royal National Orthopaedic Hospital, UK & notably very poignant and raw presentations from two remarkable survivors, Melia Hinks & Lauren Drews. Nobody can articulate this process better than those who have lived it.
We heard about advances in radiotherapy, liquid biopsy, proteomics, immunotherapy, surgery and prehabilitation. Presentations also explored CRISPR & multi-omic screening to identify potentially targetable treatment resistance in paediatric osteosarcoma, alongside B7-H3 CAR-T research & its potential application in young patients.
For CRBF, these are developments we need to understand early. Not every promising study will become a treatment, & some research remains preclinical, so there’s a need to stay close to the science, ask informed questions, assess the evidence & help patients and families understand credible options as they emerge.
Equally important on the programme was the focus on life beyond treatment, including surgical function, prosthetics, rehabilitation, fertility, survivorship, psychosocial challenges & long-term recovery.
The meeting reinforced the importance of collaboration. Sarcoma is rare, & progress depends on clinicians, researchers, allied health professionals, advocates, patients & families working together across institutions and borders.
Collaboration today. Better outcomes tomorrow